Status:
UNKNOWN
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC
Lead Sponsor:
Jiangnan University
Collaborating Sponsors:
Affiliated Hospital of Jiangnan University
Conditions:
Castration-resistant Prostate Cancer
Eligibility:
MALE
18-100 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to compare the therapy effects and clinical safety of a regulatory metabolic compound, coenzyme A (CoA) with a marketed drug, abiraterone, in Chinese patients with castrat...
Detailed Description
Prostate Cancer (PCa) has developed into the second most common cancer in men. In The United States, PCa has the highest morbidity in man. In China, the incidence rate is lower than in Europe and the ...
Eligibility Criteria
Inclusion
- \- 18-100 years of age combined use with abiraterone or enzalutamide CRPC
Exclusion
- \- pregnancy acute liver disease or hepatic dysfunction, as determined by levels of alanine aminotransferase (ALT) or aspartate aminotransferase levels (AST) more than 2-fold the upper normal limit nephrotic syndrome or serum creatinine (Cr) ≥2-fold the upper normal limit and creatine phosphokinase (CK) more than 3-fold the upper normal limit primary hypothyroidism psychiatric patients poorly controlled hypertension, as indicated by a Systolic Blood Pressure \>180 mmHg or Diastolic Blood Pressure \>110 mmHg using contraceptive agent using immunosuppressive drugs, prohibited medication or other non-PCa drugs long-term using CoA drug
Key Trial Info
Start Date :
March 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04839055
Start Date
March 18 2021
End Date
May 1 2021
Last Update
April 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jiangnan University
Wuxi, Jiangsu, China, 214000